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Abstract: Background: As part of the efforts to find natural alternatives for cancer treatment and to
overcome the barriers of cellular resistance to chemotherapeutic agents, polymeric nanocapsules
containing curcumin and/or methotrexate were prepared by an interfacial deposition of preformed
polymer method. Methods: Physicochemical properties, drug release experiments and in vitro
cytotoxicity of these nanocapsules were performed against the Calu-3 lung cancer cell line. Results:
The colloidal suspensions of nanocapsules showed suitable size (287 to 325 nm), negative charge
(−33 to −41 mV) and high encapsulation efficiency (82.4 to 99.4%). Spherical particles at nanoscale
dimensions were observed by scanning electron microscopy. X-ray diffraction analysis indicated that
nanocapsules exhibited a non-crystalline pattern with a remarkable decrease of crystalline peaks
of the raw materials. Fourier-transform infrared spectra demonstrated no chemical bond between
the drug(s) and polymers. Drug release experiments evidenced a controlled release pattern with
no burst effect for nanocapsules containing curcumin and/or methotrexate. The nanoformulation
containing curcumin and methotrexate (NCUR/MTX-2) statistically decreased the cell viability of
Calu-3. The fluorescence and morphological analyses presented a predominance of early apoptosis
and late apoptosis as the main death mechanisms for Calu-3. Conclusions: Curcumin and methotrexate
co-loaded nanocapsules can be further used as a novel therapeutic strategy for treating non-small-cell
lung cancer.
Keywords: Calu-3 cell line; cancer chemotherapy; drug resistance; poly(ε-caprolactone);
poly(ethylene glycol)
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1. Introduction
Lung cancer is the deadliest of all cancers in the world. Sudden changes in lifestyle, environmental
pollution, and smoking are strongly related to the development of lung cancer [1,2]. Treatment for lung
cancer is typically guided by stage, although individual factors, such as overall health and coexisting
medical conditions, are also important. Chemotherapy is beneficial at most stages of the disease,
although it and radiation therapy are curative in only a minority of patients. The failure of chemotherapy
in lung cancer treatment is mainly due to resistance mechanisms against chemotherapeutic agents,
which result in a lack of therapeutic response [3,4]. Resistance phenomenon can occur by efflux
pumps as P-glycoprotein (P-gp), which is expressed in human cells and acts as a localized drug
transport mechanism, actively exporting drugs out of the cell [3,5,6]. In that sense, the efflux
mechanism shows great clinical importance on lung cancer treatment and several compounds with
P-gp inhibitor properties have been studied [7] to modulate chemotherapy resistance and to provide a
more pronounced effect to chemotherapeutic drugs.
Curcumin (CUR) is a polyphenol obtained mainly from turmeric, the rhizome of Curcuma longa L.
(Zingiberaceae), which is widely used in cooking as a spice and color additive due to its characteristic
taste and deep yellow coloration [8,9]. CUR has demonstrated a variety of biological properties, such as
antioxidant, anti-inflammatory, antimicrobial, and antitumor properties [8,10,11]. CUR has also shown
therapeutic feasibility in improving wound healing activities by the use of nanotechnology-based
delivery systems [11]. Moreover, CUR is a non-competitive inhibitor of P-gp by blocking the ATP
hydrolysis process in efflux pump, which also paves the way for its use against lung cancer cells [7,12].
Despite these interesting effects, CUR has some disadvantages, such as its low aqueous solubility, low
photostability, limited absorption, low bioavailability, rapid metabolism and elimination [13].
Methotrexate (MTX) is a well-known cytotoxic agent, which competitively and irreversibly inhibits
dihydrofolate reductase, an enzyme that participates in tetrahydrofolate synthesis [14,15]. It is currently
used in lung cancer treatment alone or along with other chemotherapeutic agents by oral and parenteral
routes. High doses of MTX may circumvent at least two known mechanisms of resistance to this
drug, membrane transport and high levels of the target enzyme. However, MTX can cause substantial
toxicity by its systemic administration and can lead to remarkable side effects, such as hepatotoxicity,
bone marrow depression, leucopenia, among others [16,17]. In that sense, the traditional use of this
drug has two main problems when used against lung cancer: (a) its efflux from cancer cells by P-gp
and (b) its high toxicity at usual therapeutic doses [18,19]. Thereby, new strategies to overcome these
limitations are required.
Some controlled release strategies have been reported in the literature concerning the co-delivery
of CUR and MTX. Dey et al. [20] developed gold nanoparticles containing CUR and MTX and evaluated
their cytotoxic effect on C6 glioma cells and MCF-7 breast cancer cells. Curcio et al. (2018) [21]
obtained pH-responsive polymersomes by self-assembling of a carboxyl-terminated PEG amphiphile
achieved via esterification of PEG diacid with PEG40stearate. A highly hemocompatible co-delivery
system of CUR and MTX was obtained. Vakilinezhad et al. [22] prepared PLGA nanoparticles for the
co-administration of MTX and CUR as a potential breast cancer therapeutic system. Even though these
authors reported a burst release from such nanoparticles, higher cytotoxicity was demonstrated against
SK-Br-3 breast adenocarcinoma cell line. Curcio et al. [23] effectively delivered MTX to breast cancer
cells by the use of a nanocarrier system derived from the self-assembly of a dextran-CUR conjugate
prepared via enzyme chemistry with immobilized laccase acting as a solid biocatalyst. However, to the
best of our knowledge, no previous paper was devoted to the preparation of co-loaded CUR and MTX
nanocapsules using poly(ε-caprolactone) (PCL) as biodegradable polymer wall and poly(ethylene
glycol) (PEG) as coating polymer focused on treating lung cancer.
Polymeric nanocapsules (NCs) are attractive colloidal systems to develop formulations containing
labile and toxic substances. By definition, NCs are vesicular systems composed of a core, generally oily,
surrounded by a polymer wall [24]. These carriers can present several advantages such as enhancing
the dissolution process, increasing the therapeutic index, providing controlled delivery and achieving
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protection from the photo and chemical degradation [25]. Therefore, NCs can circumvent limitations
provided by both CUR and MTX since they allow drug protection against degradation, improve
bioavailability, and reduce possible side effects. In particular, NCs can reach target tissues, certain
affected organs, and tumors due to their superior features as small particle size, large surface area,
Brownian motion, and surface functionality which could provide higher cytotoxic effect even at low
doses of the chemotherapeutic agents [11,13]. Moreover, the two-drug combination into NCs can
produce a higher objective response since CUR can potentiate MTX activity by delaying its efflux from
the lung cancer cells.
Taking all these factors into consideration, this study was devoted to developing NCs for
co-administration of CUR and MTX to provide a controlled release and a synergistic cytotoxic effect on
non-small-cell lung cancer cell (Calu-3) growth. Moreover, in vitro studies were performed to evaluate
the cytotoxic mechanism of these co-loaded NCs against Calu-3 cells.
2. Results and Discussion
2.1. Preparation and Characterization of Polymeric Nanocapsules (NCs) Containing Curcumin (CUR) and/or
Methotrexate (MTX)
Nanocapsules with or without CUR and/or MTX were successfully obtained by the interfacial
deposition of the preformed polymer method. Formulations containing no CUR showed a liquid
aspect with a slightly bluish-white opalescent coloring. However, CUR-loaded nanocapsules presented
a liquid aspect and an intense yellow color.
2.1.1. Determination of Mean Diameter, Polydispersity Index, and Zeta Potential
Results of particle size, polydispersity, and zeta potential are summarized in Table 1. CUR and/
or MTX-loaded and non-loaded NCs revealed mean sizes between 287.83 and 325.16 nm with a
polydispersity index (PDI) varying from 0.290 to 0.351, which represent a certain system homogeneity.
Table 1. Mean diameter, polydispersity index (PDI), zeta potential, and encapsulation efficiency (EE) of
the obtained CUR and/or MTX-loaded and non-loaded nanocapsules.
Formulation Mean Particle Size *(nm) PDI *
Zeta Potential *
(mV) EE * (%)
NCUR/MTX-0 313.30 ± 48.20 0.351 ± 0.15 −39.83 ± 2.46 -
NCUR-1 307.26 ± 29.40 0.323 ± 0.07 −38.80 ± 7.45 99.4 ± 0.51
NCUR-2 315.96 ± 10.30 0.351 ± 0.02 −41.20 ± 7.20 98.7 ± 0.66
NMTX-1 287.83 ± 28.00 0.290 ± 0.11 −40.60 ± 5.80 88.9 ± 0.47
NMTX-2 298.60 ± 25.00 0.292 ± 0.01 −38.96 ± 1.60 83.3 ± 0.42
NCUR/MTX-1 312.03 ± 23.60 0.344 ± 0.05 −39.43 ± 6.26 99.1 ± 0.63 (CUR)84.4 ± 0.57 (MTX)
NCUR/MTX-2 325.16 ± 28.90 0.351 ± 0.03 −33.40 ± 3.29 99.3 ± 0.54 (CUR)82.4 ± 0.44 (MTX)
* Values are depicted as mean ± standard deviation (SD).
In general, NCs obtained by the interfacial deposition of preformed polymer method have
demonstrated mean diameters between 200 and 300 nm and PDI between 0.2 and 0.3, particularly
for the works carried out using poly(lactic-co-glycolic acid) and PCL [26]. However, NCs of larger
diameter may be related to the presence of PEG in their composition. PEG chains create a more viscous
organic phase, which affects its dispersion into the aqueous phase during stirring and leads to higher
particle sizes with broader polydispersity [27].
Also, other aspects may directly influence the particle diameter in nanosystems. One of them is
the oil used for preparing nanocapsules that influences some of the core structure properties, such as
viscosity, hydrophobicity, and surface tension [28]. PDI values close to 0 are considered monodisperse
and greater than 0.5 indicate heterogeneous dispersion [29]. Taking all these into account, suitable
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nanometric-scaled size and adequate polydispersity were recorded for NCs with or without CUR
and/or MTX.
Negative zeta potential values were observed for all the colloidal suspensions of nanocapsules
(Table 1). Zeta potential analysis allows identifying the electrical charges that occur on the surface of
the nanoparticles. Particles are regarded as stable when their zeta potential values are higher than
± 30 mV [30]. Moreover, negative values were achieved for NCs on account of the anionic nature of
PCL due to the presence of carboxylic acid functional groups [28]. The statistical analysis showed that
mean diameter, PDI and zeta potential were similar for the formulations with or without CUR and/or
MTX (p > 0.05).
2.1.2. Encapsulation Efficiency
The encapsulation efficiency (EE) of CUR and/or MTX-loaded NCs are also depicted in Table 1.
Mean EE values higher than 98.7% were obtained for formulations containing CUR alone or in
combination with MTX. These values are attributed to the poor aqueous solubility of CUR (3.12 µg.mL−1
at 25 ◦C) [31], which avoided its partitioning in the aqueous phase. For those nanocapsules containing
MTX, mean values varying from 82.4% (NCUR/MTX-2) to 88.9% (NMTX-1). These values are higher
than 70%, hence suitable for nanocapsules containing lipophilic compounds as MTX (aqueous solubility
of 2.60 mg·mL−1 at 20 ◦C) [32] when emulsion–diffusion methods were used [33]. These EE values
were further used for obtaining final concentrations in µmol·L−1 during in vitro cell culture-based
assays. For formulations containing both CUR and MTX, the EE compensation was performed using
MTX due to its lower content in co-loaded NCs.
2.1.3. Field Emission Scanning Electron Microscopy (FESEM)
Nanoscale dimensions were registered for CUR and/or MTX-loaded and non-loaded NCs when
their images were assessed by FESEM (Figure 1). NCs were spherically-shaped and had a smooth
surface. Their particle size and PDI were similar to those previously recorded [25] by photon correlation
spectroscopy. Also, it was found that even after changing CUR and/or MTX concentrations, their
morphologies were similar and no drug crystals were seen on their surfaces.
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2.1.4. X-ray Diffraction (XRD)
The diffractograms obtained for pure drugs (CUR and MTX), polymers (PCL and PEG 6000), and
nanocapsules NCUR-1, NCUR-2, NMTX-1, NMTX-2, NCUR/MTX-0, NCUR/MTX-1, and NCUR/MTX-2
are shown in Figure 2. CUR presented typical peaks at 2θ values of 8.85◦, 14.25◦, 17.04◦, and 23.10◦
as previously reported [34,35], which confirmed its crystalline nature. MTX showed main crystalline
peaks at 9.16◦, 12.8◦, 19.42◦, and 26.74◦ as previously described [36]. Also, PCL revealed two crystalline
peaks at 21.59◦ and 23.72◦. XRD data for PEG 6000 showed 2θ values at 19.17◦ and 23.41◦.
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Figure 2. Diffractograms of CUR, MTX, PCL, PEG 6000, and CUR and/or MTX-loaded and non-loaded
NCs obtained by XRD analysis.
CUR and/or MTX-loaded and non-loaded NCs exhibited similar non-crystalline pattern with
a remarkable decrease of crystalline peaks from the drug(s) and polymers. In that sense, drug
amorphization was demonstrated for all CUR and/or MTX-loaded formulations. This behavior is
related to the molecular dispersion of such drugs when NCs were obtained using the interfacial
Molecules 2020, 25, 1913 6 of 19
deposition of preformed polymer method. Solid-state substances may have crystalline and/or
amorphous characteristics. In general, the amorphous solids are more soluble than those in the
crystalline state due to the free energies present in the dissolution process. In the amorphous state,
molecules are randomly arranged and, therefore, lower energy is required to separate them, resulting
in a faster dissolution when compared to the crystalline form [37]. Therefore, the amorphous pattern of
CUR and/or MTX into NCs is considered to be advantageous because it allows the drug(s) dissolution
and leads to drug(s) diffusion through the polymer wall, resulting in a sustained release of the
encapsulated drug(s) [34,38].
2.1.5. Fourier-Transform Infrared Spectroscopy (FTIR)
The FTIR spectra recorded for CUR, MTX, PCL, PEG 6000, physical mixture, and CUR and/or
MTX-loaded and non-loaded NCs are depicted in Figure 3.
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Figure 3. FTIR spectra of CUR, MTX, PCL, PEG 6000, physical mixture, and CUR and/or MTX-loaded
and non-loaded NCs.
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The FTIR spectrum of pure CUR presented the typical bands previously reported [35,39,40].
A sharp band at 3508 cm−1 and a broad band at 3387 cm−1 were assigned to the stretching of –OH
group. Stretching vibrations of the carbonyl group and C–C bond of benzene ring were observed at
1627 cm−1 and 1510 cm−1, respectively. CUR showed a bending vibration at 1427 cm−1 assigned to
–CH group connected to the benzene rings. A band at 1276 cm−1 was recorded for C–O stretching
vibration. Two bands at 1155 cm−1 and 1028 cm−1 were assigned to stretching vibrations of C–O from
ether group and C–O–C group, respectively. Bands at 960, 813, and 713 cm−1 were related to bending
vibrations of the C–H bond of alkene groups.
MTX presented bands at 3412 and 3387 cm−1 assigned to the stretching vibration of amine groups.
A band at 2927 cm−1 was related to stretching of the O–H group from a carboxylic acid. The stretching
of the C=O bond was observed at 1645 cm−1 while the stretching of N-H bong from amide was
recorded at 1600 cm−1. Stretching bands at 1500, 1543, and 1448 cm−1 were assigned to the aromatic
ring. A band at 1207 cm−1 was related to the stretching of the C–O bond from carboxylic acid [41].
PCL presented an intense band at 1730 cm−1, corresponding to the stretching of the C=O group
from aliphatic esters. Two bands at 2943 and 2864 cm−1 were attributed to the asymmetric and
symmetric stretching vibrations of –CH2 group, respectively. Stretching bands at 1174 and 1043 cm−1
were assigned to C–O bond.
The FTIR spectrum of PEG exhibited its typical broad band at 3520 cm−1, corresponding to the
stretching of –OH group. In addition, two bands at 2883 cm−1 and 1110 cm−1 were assigned to –CH
group from an aliphatic chain and asymmetric stretching of C–O–C from dialkyl ethers, respectively.
Bands at the same wavenumber range of FTIR spectrum to those recorded for the physical
mixture was observed for CUR and/or MTX-loaded NCs. Considering the mild nanoencapsulation
conditions used, no covalent functionalization occurred among polymers and drugs when formulations
were obtained.
2.2. In Vitro Drug Release Study
NCUR-2, NMTX-1, and NCUR/MTX-2 were initially chosen for in vitro drug release experiments
due to their appropriate morphologies and sizes, suitable drug loadings and encapsulation efficiencies,
and high amorphization of the drug(s) into NCs. The release profiles for free drugs and these NCs
recorded by a dialysis method are summarized in Figure 4.
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Free CUR and free MTX showed drug release patterns with a fast diffusion in the dissolution
medium used. Free CUR achieved a mean drug-released value of 80% at 41 min of the experiment.
For free MTX, a mean drug release of 80% was obtained at 195 min of the experiment. NCUR-2 released
80% of CUR at 2,640 min (44 h). NMTX-1 released 80% of MTX at 8,160 min (136 h). NCUR/MTX-2 had
a mean drug release of 80% at 4,140 min (69 h) and 5,400 min (90 h), respectively for CUR and MTX.
Therefore, NCs demonstrated prolonged release profiles with no burst effect in comparison to free
drugs. Vakilinezhad et al. [22] described PLGA nanoparticles containing CUR and MTX with an initial
burst release that was attributed to the drug dispersion into the superficial layers of these particles.
In the present study, a typical core-shell structure was strategically planned to avoid this effect and to
achieve a prolonged drug release for circumventing the administration of multiple doses per day of
chemotherapy [42].
Considering the release profiles obtained for NCs, the difference in the release rate could be
explained by the concentration gradient between each formulation and the dissolution medium.
At higher drug concentrations, this process was faster since this gradient was the driving force for drug
dissolution. Moreover, at higher drug-loading concentration, CUR and/or MTX could be distributed
near to the nanocapsules surface providing a more rapid in vitro release [43]. In that sense, NCUR-2,
prepared at the higher theoretical drug concentration of 3.0 mg·mL−1, presented a faster dissolution
and reached a complete release in almost 2 days. On the other hand, NMTX-1, obtained at the
lowest theoretical drug concentration of 0.1 mg·mL−1, revealed a very slow dissolution rate in about
7 days. The co-loaded formulation NCUR/MTX-2 presented the best dissolution features for controlling
drug release. The theoretical drug concentrations proposed for NCUR/MTX-2, 0.5 mg·mL−1 of CUR
and 0.3 mg·mL−1 of MTX, achieved a suitable intermediate dissolution rate in about 3 days. In this
formulation, the release behavior of these drugs was closer as depicted in Figure 4, when compared to
the other formulations tested. This performance is desired as it could ensure a simultaneous effect
in vivo to provide both chemotherapeutic activity and inhibition of P-gp.
2.3. In Vitro Cell Culture-Based Assays
2.3.1. Cell Viability by MTT and SRB Tests
NCUR-2, NMTX-1, and NCUR/MTX-2 were used for cell culture-based assays due to their known
drug release profiles. In order to explore whether or not these formulations had a cytotoxic effect on
the Calu-3 cell line, MTT and SRB assays were first performed. The cell viability results for NCUR-2 at
high drug concentrations and NMTX-1 at low drug concentrations are shown in Table 2.
Table 2. Cell viability of Calu-3 by MTT and SRB assays after its treatment with NCUR-2 and NMTX-1
at different concentrations for 72 h.




0 100.00 ± 1.60 99.98 ± 1.75
25 91.48 ± 3.36 88.30 ± 4.01
50 87.74 ± 5.62 60.68 ± 6.10 ***
100 49.91 ± 5.73 *** 33.87 ± 3.07 ***
200 4.16 ± 0.67 *** 3.32 ± 0.47 ***
NMTX-1
0 100.00 ± 0.95 99.79 ± 1.22
0.5 100.37 ± 1.96 96.10 ± 2.57
1 100.60 ± 2.15 93.01 ± 4.48
2 99.53 ± 1.67 90.85 ± 3.80
4 93.90 ± 4.60 90.78 ± 4.67
Results are expressed as mean ± standard error of the mean from 4 independent experiments. Asterisks denote
significance levels compared to control: significantly different, *** p < 0.0001.
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NCUR-2 significantly reduced Calu-3 viability at 200 and 100 µmol·L−1 for both MTT and SRB
assays. This formulation also provided a significant reduction of cell viability at 50 µmol·L−1 for the
SRB test. No statistically significant decrease was observed for other concentrations tested of NCUR-2
and for all concentrations investigated of NMTX-1.
In this study, CUR demonstrated cytotoxicity only at high concentrations. This effect may be
related to the nanoencapsulation procedure since PCL/PEG NCs may have provided a controlled drug
release during the 72 h assays, resulting in low concentrations of released CUR in contact within Calu-3
cells. Different results were observed when free CUR was used. Dhanasekaran et al. [44] investigated
the effect of CUR on KG-1 cells using MTT reduction assay, where CUR achieved a dose-dependent
reduction in cell viability at different exposure times. Cell viability was reduced to 57% at 50 µmol·L−1
for 24 h and to 20% at 100 µmol.L−1 for 48 h.
Although these data for pure CUR are more attractive, its free form is not a suitable option
for its clinical use. CUR presents several problems related to its in vivo use due to its low aqueous
solubility, low bioavailability, rapid hepatic metabolism, high decomposition rate at neutral or basic
pH, and susceptibility to photochemical degradation. CUR generates inactive metabolites when
administered orally, intraperitoneally, or intravenously, thus making it unfeasible to use in its free
form [8].
In that sense, using CUR-loaded NCs is a viable and efficient therapeutic strategy in minimizing
the negative features of CUR as well as to retain its antitumoral effect. Similar results have been
reported for different tumor cell lines. Wang et al. [45] prepared solid lipid nanoparticles containing
CUR and tested them on NCL-41299 and A549 cells. Yallapu et al. [46] obtained CUR-loaded polymeric
nanoparticles and investigated their use against A2780CP and MDA-MB-231 lines.
Also, better results were obtained from the SRB assay instead of the MTT test. These findings
were concerning to the high sensibility of SRB when cytotoxicity is investigated for cells growing
adhered to dish bottom [47]. SRB evaluates cell viability through the ability of the dye to bind to protein
components [47]. On the other hand, MTT examines the activity of mitochondrial dehydrogenase
enzymes and their respective redox potential [48].
When cells were treated with NMTX-1, no significant reduction in Calu-3 viability was observed.
This result is related to the very slow dissolution rate of MTX and the resistance phenomenon, in which
MTX is a well-known substrate of P-gp [18,19]. Calu-3 is a tumor cell line that can express P-gp [49].
Therefore, lower intracellular accumulation of MTX was obtained since P-gp efflux pump was activated
and led to the removal of the antitumor drug from within the cell.
To overcome this resistance mechanism, a co-loaded formulation (NCUR/MTX-2) was proposed
since CUR even at low doses could block P-gp and could ensure the antitumor effect expected for
MTX. The cell viability by MTT and SRB techniques of Calu-3, when treated with NCUR/MTX-2,
is demonstrated in Figure 5.
NCUR/MTX-2 showed a significant reduction in Calu-3 cell viability by MTT procedure when
9.88:4 and 4.94:2 ratios of CUR:MTX were tested. For SRB assay, all concentrations (9.88:4; 4.94:2;
and 2.47:1 ratio) provided a statistically significant decrease in tumor cell viability.
NMTX-1 at different drug concentrations of 1, 2, and 4 µmol·L−1 did not reduce Calu-3 viability
when tested alone. However, co-loaded formulations containing the same MTX concentrations and
low CUR concentrations achieved a statistical reduction of cell viability. This positive result may be
due to the suitable dissolution profiles and the P-gp inhibition. NCUR/MTX-2 released both CUR
and MTX in almost 72 h that was indeed the time interval during the in vitro cell culture-based assay
was performed. Also, it is possible to infer that low CUR concentration in NCUR/MTX-2 plays a
remarkable role as P-gp inhibitor, which allows that MTX remains within the cell and performs its
antimetabolic/antitumor function. The effect of CUR was attributed only to its capacity of blocking P-gp
because this drug demonstrated cytotoxicity against Calu-3 at concentrations higher than 50 µmol.L−1
as represented in Table 2. Dey et al. [20] studied alginate-stabilized gold nanoparticles containing
CUR and MTX and investigated their effect on C6 glioma and MCF-7 cancer cells. Cell viability was
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reduced by the use of CUR:MTX ratios of 42:41 and 21:20.5 µmol·L−1. In this study, a statistically
significant decrease in tumor cell viability was observed by the use of NCs containing CUR even at
lower concentrations than those reported in the literature [13].
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Figure 5. Cell viability of Calu-3 by MTT and SRB assays after its treatment with NCUR/MTX-2 at
different (low) concentrations for 72 h. Results are expressed as mean ± standard error of the mean from
4 independent experiments. Asterisks denote significance levels compared to control: significantly
different, ** p < 0.001 and *** p < 0.0001.
Another mechanism that may be responsible for the improved cytotoxicity of MTX by CUR is
the increase of folate receptors (FRs) expression. FRs are transport systems that show a high affinity
for folate and are expressed in large numbers of cancer cells. They are important for cell uptake of
folic acid for its metabolism and cell division. However, MTX use can lead to cell resistance since this
drug reduces FRs activity [50]. Furthermore, polysorbate 80, a pharmaceutical excipient used as a
surfactant during NCs preparation, is a well-known P-gp inhibitor. Its molecules insert themselves
between lipid tails of the lipid bilayer and fluidize the cell membrane. It may also interact with the
bilayer’s polar heads and change the hydrogen bond or ionic bond forces which may contribute to its
inhibitory action against P-gp [51]. In that sense, NC composition may enhance the effect of efflux
pump inhibition provided by CUR and may lead to improved cytotoxicity against non-small-cell lung
cancer cell growth even at low doses of CUR and MTX.
Taking all these into account, the combination of low doses of CUR and MTX by the use of
colloidal suspensions of NCs may be a promising strategy for the treatment of lung cancer, reducing
the toxic effects associated with the use of high doses of MTX [44,50].
2.3.2. Combination Index
The next question addressed was whether NCUR/MTX-2 could provide a synergistic effect on
Calu-3 lung cancer cells using MTT cytotoxicity assay. To reveal the synergistic activity, a combination
index (CI) was performed considering the half-maximal inhibitory concentration (IC50) data of separate
and combined cytotoxic effects of NCs containing CUR and/or MTX. IC50 (mean value ± SD) for
CUR from NCUR-2 was 100.18 ± 3.74 µmol.L−1. NMTX-1 presented an IC50 of 23.06 ± 1.13 µmol·L−1.
IC50 for CUR and MTX from NCUR/MTX-2 were 69.81 ± 3.07 and 1.89 ± 0.06 µmol·L−1, respectively.
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Thereby, the CI value achieved was 0.78. In brief, the CI equal to 1 indicates that the two drugs
have additive effects, the CI lower than 1 suggests a synergism and the CI higher than 1 indicates
antagonism [52]. Consequently, a synergistic activity was demonstrated for NCUR/MTX-2 due to
the combination of these drugs induced greater cytotoxicity against Calu-3. This finding shows that
cytotoxic chemotherapy using NCUR/MTX-2 appears to be a promising strategy for the treatment
of non-small-cell lung cancer which merits further preclinical and clinical investigation since it has
allowed a suitable effect even at low chemotherapeutic doses into this nanocarrier.
2.3.3. Cell Death Pattern through Acridine Orange/Ethidium Bromide (AO/EB) Test
Considering the results observed for NCUR/MTX-2 in reducing cell viability of Calu-3, the cell
death pattern of this formulation was investigated after the 24 h treatment by AO/EB staining to verify
the death mechanism.
The cytotoxic effect of NCUR/MTX-2 formulations can be observed in Figure 6. The control
showed viable cells with normal and bright green nuclei (Figure 6A, white arrows). NCUR/MTX-2
resulted in early-stage apoptotic cells that were marked by crescent-shaped or granular yellow-green
acridine orange nuclear staining (Figure 6B, yellow arrows), and late-stage apoptotic cells showing
concentrated and asymmetrically located orange nuclear ethidium bromide staining (Figure 6B,
blue arrow). In addition, the occurrence of apoptotic membrane blebbing (Figure 6B, red arrow) was
verified since membrane blebbing is required for redistribution of fragmented DNA from the nuclear
region into membrane blebs and apoptotic bodies [53]. No necrotic cell was observed after treating the
Calu-3 cells with the co-loaded formulation.
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disappear by unspecific DNA fragmentation [55]. In that sense, the co-loaded formulation was able
to provide a Calu-3 death pattern by a carefully regulated energy-dependent process, characterized
by programmed cell death, which is a widespread component of both health and disease. Moreover,
apoptosis is a superior mechanism for feasible therapeutic interventions on the pathophysiology of
lung cancer.
3. Materials and Methods
3.1. Materials
Curcumin (CUR, ≥94% curcuminoid content, Sigma-Aldrich, St. Louis, MO, USA), methotrexate
(MTX, >99% pure, Fermion, Espoo, Finland), poly(ε-caprolactone) (PCL, Mw 10,000–14,000 g.mol−1,
Sigma-Aldrich), poly(ethylene glycol) 6000 (PEG, Mw 5,400–6,600 g.mol−1, Cromato Produtos Químicos,
Diadema, Brazil), sorbitan monooleate (Span 80, Oxiteno, Mauá, Brazil), polysorbate 80 (Tween 80,
Delaware, Porto Alegre, Brazil), medium chain triglycerides (MCT, 99% pure, Focus Química,
São Paulo, Brazil), acridine orange base (AO, Sigma-Aldrich), ethidium bromide (EB, Sigma-Aldrich),
methylthiazolyldiphenyltetrazolium bromide (MTT, Sigma-Aldrich), sulpho-rhodamine B (SRB,
Sigma-Aldrich), penicillin-streptomycin (Sigma-Aldrich), and acetone (≥99.9% pure, Vetec Química,
Rio de Janeiro, Brazil) were used as received. HPLC-grade methanol was purchased from Tedia (Rio de
Janeiro, Brazil). RPMI 1640 medium and fetal bovine serum were obtained from Vitrocell (Campinas,
Brazil). Water was purified in a Milli-Q Plus water purification system (Millipore, Bedford, MA, USA).
All other solvents and reagents were analytical grade. The Calu-3 cell line was obtained from the Bank
of Cells of Rio de Janeiro (BCRJ, Brazil) and was kindly provided by Dr. Katia Sabrina Paludo.
3.2. Preparation of Polymeric Nanocapsules (NCs) Containing Curcumin (CUR) and/or Methotrexate (MTX)
The interfacial deposition of the preformed polymer method was used for preparing NCs
containing CUR and/or MTX [20]. Six different formulations (Table 3) were obtained depending on
the amount of CUR and/or MTX in their composition. Briefly, PCL and PEG 6000 were solvated in
the organic phase containing span 80, CUR and/or MTX, MCT, and acetone. This phase was carefully
added to the aqueous phase containing tween 80 and purified water under vigorous magnetic stirring
at 45 ◦C. The obtained colloidal emulsion was kept under magnetic stirring for 10 min. The organic
solvent was then quickly removed by evaporation under reduced pressure at 40 ◦C. Non-loaded
nanocapsules were also prepared as the negative control. All formulations were obtained in triplicate
from three different batches. For providing a comparative analysis, a physical mixture of polymers and
drugs (PM PCL/PEG/CUR/MTX) at the same molar ratio was prepared by mortar and pestle mixing
before characterization procedures.
Table 3. Composition of polymeric nanocapsules containing curcumin (CUR) and/or methotrexate (MTX).
Formulation
Composition







NCUR/MTX-0 - - 0.020 0.080 0.077 0.300 27 0.077 53
NCUR-1 0.010 - 0.020 0.080 0.077 0.300 27 0.077 53
NCUR-2 0.030 - 0.020 0.080 0.077 0.300 27 0.077 53
NMTX-1 - 0.001 0.020 0.080 0.077 0.300 27 0.077 53
NMTX-2 - 0.003 0.020 0.080 0.077 0.300 27 0.077 53
NCUR/MTX-1 0.030 0.001 0.020 0.080 0.077 0.300 27 0.077 53
NCUR/MTX-2 0.005 0.003 0.020 0.080 0.077 0.300 27 0.077 53
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3.3. Characterization of Polymeric Nanocapsules (NCs) Containing Curcumin (CUR) and/or
Methotrexate (MTX)
3.3.1. Determination of Mean Diameter, Polydispersity Index, and Zeta Potential of NCs
Mean particle size, polydispersity, and zeta potential were measured at 25 ◦C using a Zetasizer
Nanoseries ZS903600 apparatus (Malvern Instruments, Malvern, UK). Each sample was previously
diluted in water (1:500) and each analysis was performed at a scattering angle of 90◦ and a temperature
of 25 ◦C for mean particle size and polydispersity measurements. For zeta potential, each sample was
placed into the electrophoretic cell where a potential of ± 150 mV was used.
3.3.2. Encapsulation Efficiency
CUR and/or MTX content of NCs was determined by the indirect method. In brief, suspensions of
nanocapsules were submitted to a combined ultrafiltration/centrifugation using centrifugal devices
(Amicon®® 10.000 MW, Millipore, Bedford, MA, USA) at 2200 g during 30 min in triplicate. Free CUR
and/or MTX were determined in ultrafiltrate using an HPLC method in a Merck-Hitachi Lachrom
equipment (Tokyo, Japan), interface D-7000, UV detector module L-74000, equipped with pumps L-7100
and an integral degasser, controller software (Chromquest, Thermo Fisher Scientific, Incorporated,
Pittsburgh, PA, USA), and manual injector (Rheodyne, Rohnert Park, CA, USA) equipped with a 20 µL
injector loop and a 100 µL syringe (Microliter 710, Hamilton, Bonaduz, Switzerland). Chromatographic
separation was accomplished using a Inertsil®®ODS3 (GL Sciences, Torrance, CA, USA) reversed-phase
analytical column (150 mm × 4.6 mm, 5 µm) and a GL Sciences Inertsil®® ODS3 guard cartridge
system (10 mm × 4 mm, 5 µm) at room temperature (20 ± 2 ◦C) using UV detection at 261 nm. Gradient
elution was carried out using a mobile phase consisted of methanol:water acidified with 0.5% acetic
acid at a flow rate of 1.0 mL.min−1. The mobile phase gradient program was as follows: it was started
at 44% MeOH for 3 min, increased to 90% MeOH in 5 min, held constant until 11 min, then returned to
44% MeOH in 12 min. The encapsulation efficiency (EE, %) was calculated using Equation (1):
EE(%) =
total drug content− f ree drug content
total drug content
× 100 (1)
3.3.3. Field Emission Scanning Electron Microscopy (FESEM)
The freeze-dried formulations were mounted on aluminum stubs and sputtered with gold (IC-50
Ion Coater, Shimadzu, Kyoto, Japan). Morphological analysis was performed and photomicrographs
were prepared using a Mira3 LM FESEM (Tescan, Brno, Czech Republic) at an accelerating voltage of
5 kV.
3.3.4. X-ray Diffraction (XRD)
Polymeric nanocapsules were previously deposited on a glass coverslip and dried at room
temperature (25 ± 2 ◦C). XRD data were recorded in an Ultima IV diffractometer (Rigaku, Tokyo,
Japan). The 2θ value was increased from 4◦ to 50◦ at a scan rate of 0.05◦·min−1 using a Cu-Kα source
(λ = 1.5418 Å) at 30 kV and 40 mA.
3.3.5. Fourier-Transform Infrared Spectroscopy (FTIR)
FTIR analyses of raw materials, freeze-dried polymeric nanocapsules, and physical mixture were
carried out from 4000 to 400 cm−1 using a Prestige-21 IR spectrophotometer (Shimadzu, Kyoto, Japan)
in KBr pellets with 32 scans and a resolution of 4 cm−1.
3.4. In Vitro Drug Release Study
The release experiments were performed for free CUR, free MTX, and formulations NCUR-2,
NMTX-1, and NCUR/MTX-2 by dialysis diffusion procedure in phosphate-buffered saline (PBS,
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20 mmol.L−1) containing 0.1% (w/v) Tween®® 80 at pH 7.4 [21,22] by adding each sample in PBS
(1.5 mL) into a dialysis bag (Spectra/Por®® molecular porous membrane tubing, MWCO 10,000,
Spectrum Laboratories, Rancho Dominguez, CA, USA), and dialyzed against fresh PBS (13.5 mL)
at 37 ◦C and under continuous magnetic stirring of 50 rpm. Aliquots of 500 µL were withdrawn at
predetermined time intervals and replaced by the same volume of fresh medium. CUR and MTX
concentrations were determined individually in each sample by the previously described HPLC
method. The in vitro drug release assay was carried out in triplicate from three different batches.
3.5. In Vitro Cell Culture-Based Assays
3.5.1. Cell Culture
Calu-3 cell line was cultured in RPMI 1640 medium at pH 7.4, containing 10% fetal bovine serum,
supplemented with 24 mmol·L−1 sodium bicarbonate, 2 mmol·L−1 L-glutamine, 1 mmol·L−1 sodium
pyruvate, 10,000 U·L−1 penicillin, and 10 mg·L−1 streptomycin. The cultures were maintained in a
humidified oven at 37 ◦C with 5% CO2 atmosphere.
3.5.2. Cell Treatment
Calu-3 cells were seeded in 96-well plates at a density of 1.5 × 104 cells.well−1 and incubated
for 24 h in the culture medium. For assessment of cell viability and cytotoxicity, Calu-3 cell line
was incubated with the samples NCUR-2 (200.00–25.00 µmol·L−1), NMTX-1 (100.00–12.50 µmol·L−1
and 4.00–0.50 µmol·L−1) and NCUR/MTX-2 (247.00–61.75 µmol·L−1 and 9.88–2.47 µmol·L−1 to CUR;
100.00–25.00 µmol·L−1 and 4.00–1.00 µmol·L−1 to MTX) for 72 h at 37 ◦C with 5% CO2 atmosphere.
For co-loaded formulation, final concentrations were standardized using MTX due to its lower content
in NCs and EE compensation was also performed for CUR content, resulting in fractional values. Tests
were obtained using serial dilution procedure and were performed as four independent experiments
containing n = 4 samples per assay.
3.5.3. Cell Viability by Methylthiazolyldiphenyl-tetrazolium Bromide (MTT) Test
After 72 h of the treatments, 200 µL of a solution of MTT at 0.5 mg·mL–1 was added to the wells
following a standard method [56]. The cultures were then incubated at 37 ◦C for 2 h, protected from
light, until the presence of formazan crystals. The supernatant was then removed. For the solubilization
of these crystals, 200 µL of dimethyl sulfoxide was added. The spectrophotometric absorbance reading
was performed at a wavelength of 550 nm in a µQuant microplate reader (BioTek, Winooski, VT, USA).
To calculate cell viability (%), Equation (2) was used. The concentration that inhibited 50% of cell
growth (IC50) was then calculated by Probit regression [57]:
Cell viability (%) =
absorbance o f test
absorbance o f control
× 100 (2)
3.5.4. Combination Index
To define the drug-drug interaction potential from the use of NCs containing CUR and MTX
against Calu-3 cells, the combination index (CI) was calculated by Equation (3) [58] considering the
results obtained by the MTT method:







where (Dx)1 and (Dx)2 are the concentration of the tested substance 1 (CUR) and the tested substance 2
(MTX) used in the single treatment that was required to decrease the cell viability by 50% and (D)1 and
(D)2 are the concentration of the tested substance 1 (CUR) in combination with the concentration of the
tested substance 2 (MTX) that together decreased the cell viability by 50%.
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3.5.5. Cell Viability by Sulphorhodamine B (SRB) Test
For the analysis of SRB, the method described by Papazisis et al. [59] was used. In brief, Calu-3
cell line was treated with each sample for 72 h and the supernatant was then discarded. The cells were
washed with 200 µL of sodium phosphate buffer at pH = 7.4. Then, 200 µL of 10% cold trichloroacetic
acid was added and the plates were placed in the refrigerator for 30 min to fix the cells. Subsequently,
the cells were washed three times with 200 µL of distilled water and maintained for 24 h at room
temperature (20 ± 2 ◦C) to dryness. Later, 200 µL of 0.2% SRB solution was added and kept for 30 min.
The plates were then washed five times with 200 µL of 1% acetic acid and again dried for 30 min.
Finally, 150 µL of 10 mmol.L−1 TrisBase was added and the spectrophotometric absorbance reading
was performed at a wavelength of 432 nm in a microplate reader (µQuant, BioTek). Equation (2) was
also used for calculating cell viability (%).
3.5.6. Cell Death Pattern through Acridine Orange/Ethidium Bromide (AO/EB) Test
In 24-well plates, CALU-3 cells were seeded onto coverslips at the concentration of
1 × 105 cells.well−1 using RPMI 1640 culture medium. After 24 h for cell adhesion, the medium
was then discarded and NCUR/MTX-2 sample (CUR 9.88 µmol·L−1 and MTX 4.00 µmol·L−1) was
added in a volume of 500 µL. Cells were then incubated at 37 ◦C in a wet atmosphere and 5% CO2.
After 24 h treatment, the wells were washed with 200 µL of sodium phosphate buffer at pH = 7.4.
Following this, 10 µL of acridine orange/ethidium bromide dye mixture (200 µg·mL−1) was placed on a
coverslip, which was then inverted on a slide. The staining was viewed under a BX41 fluorescence
microscope (Olympus, Tokyo, Japan) with an excitation filter at 480/30 nm and emission at 535/40 nm.
The typical fields were recorded with an attached Olympus DP71 camera.
Classification of cell type to AO/EB staining was performed based on the criteria proposed by
Ribble et al. [60]. In summary, the viable cells present bright green nucleus, necrotic cells depict
orange-red fluorescence, early-stage apoptotic cells are marked by crescent-shaped or granular
yellow-green AO nuclear staining, and late-stage apoptotic cells show concentrated and asymmetrically
sited orange nuclear EB staining.
3.6. Statistical Analysis
Statistical analyses were performed using one-way analysis of variance (ANOVA), and when
necessary, the post-hoc Tukey test was used. The results were expressed as a mean ± standard error
of the mean (SEM) and mean ± standard deviation (SD). P values lower than 0.05 (p <0.05) were
considered significant. Calculations were carried out using the statistical software GraphPad Prism
version 5.03 (GraphPad Inc., San Diego, CA, USA).
4. Conclusions
In conclusion, CUR and/or MTX co-loaded PCL/PEG6000 nanocapsules were successfully
prepared by interfacial deposition of the pre-formed polymer. Nanometer-sized, monodisperse,
amorphous/non-crystalline formulations with high drug-loading efficiencies were obtained.
No changes in FTIR assignments were recorded after the nanoencapsulation procedure. In addition,
NCUR/MTX-2 provided a statistically significant decrease of Calu-3 cell viability by MTT and SRB
assays even at low concentrations of these chemotherapeutic agents. A synergistic effect was proven
by the use of this co-loaded nanocarrier. The fluorescence-morphological analysis revealed a cell
death pattern based on early and late apoptosis. No necrotic cell was observed in the Calu-3 cells
after treating with the co-loaded formulation NCUR/MTX-2. In summary, the co-loaded nanocapsules
method can be further used as a novel therapeutic strategy by intravenous or pulmonary route for
treating non-small-cell lung cancer to hold the potential for achieving therapeutic outcomes while
reducing the incidence of adverse drug effects.
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